Medicare Part D Out-of-Pocket Cap
One of the most significant Medicare changes in decades arrived January 1, 2025: the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Medicare Part D prescription drug costs — codified at 42 U.S.C. §§ 1395w-102 and 1395w-113 — eliminating the notorious "donut hole" coverage gap that had forced millions of seniors to pay full drug costs after reaching a spending threshold. Before 2025, Part D had no true out-of-pocket cap: beneficiaries hit the coverage gap at around $5,030 in total drug spending (2024) and paid a larger share of costs until reaching a catastrophic threshold, then 5% of costs indefinitely. The new $2,000 cap means that once a Medicare Part D enrollee has paid $2,000 in covered drug costs in a calendar year, their plan covers 100% of remaining costs for the rest of the year — with no further cost-sharing. The IRA also introduced a Medicare Prescription Payment Plan allowing beneficiaries to spread the $2,000 cap across 12 monthly installments rather than paying it all upfront early in the year (relevant for people who take expensive specialty drugs in January). Approximately 1.5 million Medicare beneficiaries are expected to benefit annually from the cap, with the highest savings going to those on high-cost cancer drugs, MS treatments, and other specialty medications that previously cost $10,000–$30,000/year even after insurance. The cap applies to Part D standalone plans and Medicare Advantage Part D plans alike.
Current Law (2026)
The Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000/year starting in 2025, eliminating the coverage gap ("donut hole") and providing catastrophic protection.
| Parameter | 2025+ Value |
|---|---|
| Annual OOP cap | $2,000 |
| Monthly payment option | $2,000 can be spread across 12 monthly payments |
| Insulin cap | $35/month (separate from OOP cap) |
| Vaccine cost-sharing | $0 for all Part D vaccines |
Legal Authority
- 42 U.S.C. § 1395w-102 — Prescription drug benefits (as amended by IRA — $2,000 annual out-of-pocket cap, elimination of coverage gap)
- 42 U.S.C. § 1395w-113 — Premiums and plan approval (monthly payment smoothing option for OOP costs)
- IRA Section 11001 — Part D benefit redesign
- IRA Section 11401 — $35 insulin cap
- IRA Section 11402 — Elimination of vaccine cost-sharing
How It Works
The $2,000 annual out-of-pocket cap under 42 U.S.C. § 1395w-102 (as amended by the Inflation Reduction Act) means that once a Medicare Part D enrollee has paid $2,000 in true out-of-pocket costs — the sum of your deductible payments, copays, and coinsurance on covered drugs throughout the year — all remaining covered prescription drugs cost $0 for the rest of that calendar year. "True out-of-pocket" does not include plan premiums or manufacturer discounts applied to your cost-sharing; it measures only what you actually paid out of pocket at the pharmacy. This hard cap replaces the prior structure entirely: the "donut hole" coverage gap — where beneficiaries paid higher cost-sharing on drug spending between approximately $5,000 and $8,000 in total annual costs — is gone. The previous catastrophic phase (where you paid 5% of drug costs indefinitely after a high spending threshold) is also eliminated. The IRA redesign also shifted more of the catastrophic-phase costs to drug manufacturers (a 20% manufacturer discount now required in that phase), and the same cap protections apply equally to standalone Part D plans and Medicare Advantage Part D plans.
For beneficiaries who reach the $2,000 cap early in the year — because they take a high-cost specialty drug — the Medicare Prescription Payment Plan (MP3) allows spreading the $2,000 in anticipated OOP costs across 12 equal monthly installments rather than paying them all upfront in January. The installments are interest-free and voluntary; enrollment is through your Part D plan during Open Enrollment (October 15–December 7). This converts a potentially large lump-sum pharmacy bill in the first month of the year into approximately $167/month — a meaningful cash flow improvement for beneficiaries on fixed incomes. A separate, standalone cap protects insulin users: each covered insulin prescription is capped at $35/month per prescription under IRA Section 11401, regardless of plan phase and regardless of whether you've reached the $2,000 annual OOP cap. The $35 insulin cap and the $2,000 OOP cap operate independently.
How It Affects You
If you take a high-cost specialty medication: The $2,000 annual out-of-pocket cap is the single most significant change to Medicare prescription drug coverage in decades — worth thousands of dollars per year for beneficiaries on specialty drugs. Before the IRA, a Medicare beneficiary taking a specialty drug costing $8,000/month would pay thousands in coinsurance as they moved through the donut hole. Under the IRA's new structure, effective January 2025, your true out-of-pocket costs (deductible + copays + coinsurance, but NOT premiums) are capped at $2,000 for the entire year. After reaching $2,000, all covered drugs are $0 for the rest of the year. The cap is indexed to grow slightly each year. Note: the $2,000 is measured in "true out-of-pocket" costs — manufacturer discounts don't count toward your cap.
If your drug costs usually hit the cap early in the year: The Medicare Prescription Payment Plan (MP3) lets you smooth your $2,000 cap across 12 monthly installments — approximately $167/month — rather than reaching the cap with one or two large pharmacy bills in January or February. This is interest-free and voluntary. Enrollment must be done through your Part D plan (either standalone PDP or your Medicare Advantage plan's drug coverage). If you expect to reach the $2,000 cap and currently face large out-of-pocket pharmacy bills in the first months of the year, the payment plan converts a lumpy expense into a predictable monthly budget line. Call your plan during Open Enrollment (Oct 15 - Dec 7) to enroll before the new plan year.
If you use insulin for diabetes management: The $35/month cap on each insulin prescription is separate from and in addition to the $2,000 annual cap. Each insulin product (each prescription) is capped at $35/month — you cannot be charged more at any pharmacy, in any phase of the benefit, for Medicare-covered insulin. This applies to all Part D plans. Before this cap (effective for Part D in 2023), some insulin users were paying $100-$300+ per prescription per month depending on their plan's formulary structure and the coverage phase they were in. The $35 cap has been one of the more broadly impactful provisions of the IRA for diabetic Medicare beneficiaries.
If you're a dual-eligible (Medicare + Medicaid) beneficiary: If your income qualifies you for Medicaid, you likely receive automatic Extra Help (Low-Income Subsidy) for Part D, which reduces cost-sharing well below the $2,000 cap and may eliminate most drug copays entirely. Check with your state Medicaid office.
If you haven't compared Part D plans since the $2,000 OOP cap took effect in 2025: The new cap has changed the calculus for plan selection. Previously, high-cost drug users needed to model the donut hole impact when comparing plans. Now, the plan comparison is more focused on: (1) monthly premium, (2) which formulary tier your specific drugs land on (affecting your cost-sharing before reaching the cap), and (3) which pharmacies are in the plan's preferred network (affecting your out-of-pocket prior to the cap). The Medicare Plan Finder at medicare.gov calculates your estimated annual drug costs under each available plan, including reaching the cap. Switching plans annually during Open Enrollment — if a different plan has your drugs at lower tiers — can save hundreds per year within the new cap structure.
Implementing Regulations
- 42 CFR Part 423 — Voluntary Medicare prescription drug benefit (§§ covering benefit structure, annual out-of-pocket threshold, catastrophic coverage, cost-sharing amounts, IRA/Inflation Reduction Act negotiated drug price implementation)
Pending Legislation (119th Congress)
- HR2340 — Advancing Enrollment and Reducing Drug Costs Act (Rep. Pappas, D-NH) — Auto-enrolls certain low-income Medicaid/Medicare dual eligibles into Part D Extra Help, further reducing OOP costs below the $2,000 cap
- S526 — Pharmacy Benefit Manager Transparency Act (Sen. Grassley, R-IA) — PBM transparency reforms that could reduce drug prices flowing through Part D plans, lowering total OOP spend
- S1587 — Fair Prescription Drug Prices for Americans Act (Sen. Hawley, R-MO) — International reference pricing that would reduce list prices for Part D drugs, making the $2,000 cap less binding for many beneficiaries
- HR6837 — PBM Fiduciary Act (119th Congress) — Deems PBMs fiduciaries under ERISA, requiring new compensation disclosures and barring indemnification for fiduciary breaches
- HR 8143 — Would require PDP sponsors of a prescription drug plan under Part D to provide certain information to Medicare beneficiaries. Status: Introduced.
Recent Developments
- $2,000 OOP cap effective January 2025: The IRA's $2,000 annual out-of-pocket cap on Part D prescription drug spending became effective for plan year 2025 — the most significant Medicare drug benefit change since Part D was enacted in 2003. Before 2025, Part D had no out-of-pocket cap; catastrophic drug costs fell entirely on beneficiaries after a coverage gap. The $2,000 cap benefits approximately 1.5 million Part D enrollees who previously spent more than $2,000/year on covered drugs. For insulin users, cancer patients, and beneficiaries with multiple chronic conditions requiring specialty drugs, the savings can be $5,000-$15,000+ per year.
- Medicare drug price negotiation first results (2026): The IRA's Medicare drug price negotiation resulted in the first set of negotiated prices taking effect January 2026 for 10 drugs: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/NovoLog. CMS negotiated prices averaging 38-79% below the drugs' list prices. Medicare Part D plans must cover the negotiated drugs at the negotiated prices; beneficiaries with these drugs will see the savings reflected in their cost-sharing. The Trump administration has not reversed the negotiation program, which is broadly popular.
- Part D premium increases (2025-2026): Despite the $2,000 cap benefit, Part D premiums increased in 2025-2026 as plans recalibrated their benefit designs around the cap. The average basic Part D premium rose to approximately $46/month in 2025 (up from $41 in 2024). Plans responding to the cap's redistribution of drug cost responsibility between beneficiaries and insurers made adjustments including formulary changes, utilization management, and cost-sharing structure modifications. Low-income subsidy (Extra Help) beneficiaries are largely protected from premium increases.